Soligenix, a biopharmaceutical company, announced it is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a thermostable subunit vaccine targeting the Bundibugyo virus, a strain of Ebola. The vaccine leverages Soligenix's ThermoVax platform, which stabilizes vaccines at high temperatures, aiding distribution in virus-endemic regions. This development is crucial as the Bundibugyo virus is causing an ongoing outbreak in Central Africa with high mortality and no approved vaccine. If funded, Soligenix aims to rapidly advance this vaccine to address urgent public health needs and improve global vaccination logistics.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Calix, AeroVironment, and Lucid Group. These lawsuits allege misleading statements or failure to disclose material facts...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. These lawsuits allege misleading statements or no...
Investor Jim Chanos challenged comparisons of SpaceX's IPO valuation to early tech giants like Amazon, Google, and Meta, noting SpaceX's valuation far exceeds those early multiples. Amazon went public at 3x revenues, Google at 7x, and Meta at 20x, wh...
The global surgical masks market, valued at $3.95 billion in 2024, is projected to grow at a 5.5% CAGR to reach $6.76 billion by 2034. Growth is driven by increased healthcare applications, rising infection control awareness, and more surgical proced...
SUNation Energy and Suniva have signed a definitive merger agreement to combine their businesses, with the merged company operating under the Suniva name and retaining SUNation's Nasdaq listing. The merger aims to accelerate Suniva's U.S. solar cell ...
